Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

Vaccine

Volumn 29, Issue 10, 2011, Pages 1968-1973

  Vu, David M ^a   Wong, Tracy T ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Complement; FHbp; GNA 2132; Neisseria meningitidis; NHba; Vaccine

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; FACTOR H BINDING PROTEIN; FACTOR H BINDING PROTEIN ANTIBODY; MENINGOCOCCUS VACCINE; NEISSERIAL HEPARIN BINDING ANTIGEN; NEISSERIAL HEPARIN BINDING ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNITY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; SERUM BACTERICIDAL ANTIBODY ASSAY;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; MICE; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS;

EID: 79951722492     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.075     Document Type: Article

References (27)

1. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
2. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25:3075-3079.
3. Serruto D., Spadafina T., Ciucchi L., Lewis L.A., Ram S., Tontini M., et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010, 107:3770-3775.
4. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
5. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
6. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003, 188:1730-1740.
7. Plested J.S., Welsch J.A., Granoff D.M. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 2009, 16:785-791.
8. Weynants V.E., Feron C.M., Goraj K.K., Bos M.P., Denoel P.A., Verlant V.G., et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007, 75:5434-5442.
9. Rosenqvist E., Musacchio A., Aase A., Hoiby E.A., Namork E., Kolberg J., et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun 1999, 67:1267-1276.
10. Munkley A., Tinsley C.R., Virji M., Heckels J.E. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb Pathog 1991, 11:447-452.
11. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, NHba (gna2132), NadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
12. Lucidarme J., Comanducci M., Findlow J., Gray S.J., Kaczmarski E.B., Guiver M., et al. Characterization of fHbp, nhba (gna2132), NadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009, 47:3577-3585.
13. Bambini S., Muzzi A., Olcen P., Rappuoli R., Pizza M., Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
14. Beernink P.T., Welsch J.A., Harrison L.H., Leipus A., Kaplan S.L., Granoff D.M. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007, 195:1472-1479.
15. Giuliani M.M., Biolchi A., Serruto D., Ferlicca F., Vienken K., Oster P., et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010, 28:5023-5030.
16. Frasch C.E., Mocca L.F. Strains of Neisseria meningitidis isolated from patients and their close contacts. Infect Immun 1982, 37:155-159.
17. Pajon R., Beernink P.T., Harrison L.H., Granoff D.M. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
18. Beernink P.T., Welsch J.A., Bar-Lev M., Koeberling O., Comanducci M., Granoff D.M. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 2008, 76:4232-4240.
19. Beernink P.T., Shaughnessy J., Ram S., Granoff D.M. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clin Vaccine Immunol 2010, 17:1074-1078.
20. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
21. Koeberling O., Giuntini S., Seubert A., Granoff D.M. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 2009, 16:156-162.
22. Beernink P.T., Caugant D.A., Welsch J.A., Koeberling O., Granoff D.M. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009, 199:1360-1368.
23. Beernink P.T., Granoff D.M. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008, 76:2568-2575.
24. Welsch J.A., Ram S., Koeberling O., Granoff D.M. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 2008, 197:1053-1061.
25. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
26. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
27. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998, 95:3140-3145.